Related Experiment Videos
[Relationship between cyclooxygenase (COX)-2 and malignant tumors]
Rikio Yoshimura1, Masahide Matsuyama, Kenji Tsuchida
1Department of Urology, Osaka City University Graduate School of Medicine.
Nihon Rinsho. Japanese Journal of Clinical Medicine
|October 13, 2005
Summary
Nonsteroidal anti-inflammatory drugs (NSAIDs) may reduce cancer risk by inhibiting cyclooxygenase (COX) enzymes. This review explores COX-2 expression in urological cancers and the effects of COX inhibitors.
Area of Science:
- Oncology
- Pharmacology
- Biochemistry
Context:
- Epidemiologic studies and animal experiments suggest NSAIDs reduce colorectal carcinoma incidence.
- Cyclooxygenase (COX) is the primary target of NSAIDs, inhibiting prostaglandin production from arachidonic acid.
- COX enzymes may play a role in carcinogenesis initiation and promotion.
Purpose:
- To review the expression of COX-2 in various urological cancer tissues.
- To examine the effects of COX inhibitors on urological cancers.
Summary:
- This review focuses on cyclooxygenase-2 (COX-2) expression in renal cell carcinoma, bladder tumors, prostate cancer, and testicular tumors.
- It investigates the potential of nonsteroidal anti-inflammatory drugs (NSAIDs) and their mechanism of action, COX inhibition, in the context of urological malignancies.
- The role of prostaglandins (PGs) in carcinogenesis is also discussed.
Impact:
- Highlights the potential therapeutic role of COX inhibitors in urological cancer treatment.
- Provides insights into the molecular mechanisms underlying NSAID efficacy in cancer prevention and therapy.
- Contributes to understanding the link between inflammation and cancer development in the urinary tract.